Opportunities & Solicitations

How Does This Work?

JPM-MCS offers funding opportunities to MCDC members through solicitations called Requests for Prototype Proposals (RPPs). The RPPs offer MCDC members the opportunity to propose prototype technologies to the technology requirements in each solicitation’s objective or sub-objective area. Active and Closed solicitations are listed below.


Only MCDC Members in good standing can submit whitepapers and proposals in response to solicitations. Please log-in to the MCDC Members Only Site to view complete solicitation information. If you do not have a username and password, please click here to request access.

If you are not a MCDC member and wish to become one, please click here for instructions.


INTENT TO ANNOUNCE
October 20, 2017

On October 20, 2017, the Government posted on FBO their intent to announce Requests for Prototype Proposals (RPPs) under the Other Transaction Agreement (OTA) with the MCDC. This is an intent to announce for planning purposes only and not an actual solicitation. The FBO.gov number is W15QKN-18-Z-00C9 for your reference. This Intent to Announce will result in MCDC-RPP-18-02 which will be for Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) Medical Countermeasure Systems (MCS) projects. The below is a direct link to the notice:
https://www.fbo.gov/notices/f0915306ca64854d77bbcfdf7d062ba1

For your convenience the projects the Government anticipates soliciting under this RPP (MCDC-RPP-18-02) are listed below. All five (5) projects include white paper and full proposal submission.
1. Butyrlcholinesterase Product Biophysical Characterizations, Formulation and Process Enhancement
2. Development of a Multi-dose Vial of an Injectable Opioid Antagonist
3. Development of a Naloxone Autoinjector
4. Development of an Opioid Poisoning Prophylaxis
5. Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic Evaluations

There will be no additional FBO notice when/if the RPP is announced. ATI, as the MCDC Consortium Management Firm, will notify MCDC members as well as our Interested Parties list via email. We will also post an announcement on the MCDC website at www.medcbrn.org. Please note that upon release of an actual solicitation (MCDC-RPP-18-02), only MCDC members in good standing will have access to the RPP documents describing the technical requirements and proposal preparation instructions (via the MCDC Members Only website).
ACTIVE SOLICITATIONS
MCDC-RPP-18-01
Request for Prototype Proposal (RPP) MCDC-RPP-18-01 was released October 19, 2017 and solicited White Papers followed by Full Proposals for the following Sub-Objective topics within the Detection and Treatment Objective areas. These topics have been put forth by the Joint Science and Technology Office (JSTO) of the Defense Threat Reduction Agency (DTRA), in conjunction with the JPM-MCS.

Only MCDC Members in good standing can submit White Papers and Proposals in response to this solicitation. The actual solicitation documents can been found on the MCDC Members Only site.
DET-18-01: Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial Agent
DET18-02: Development of Multiplex Molecular Diagnostics Based on CRISPR-Cas and other Synthetic Biology Approaches
TRE-18-03: Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents

Should you wish to consider membership in the MCDC, please contact us at MCDC@ati.org for more information.


Active Requests For Information
November 15, 2017

RFI-18-06-PRISM-Nucleic Acid-Based Vaccine Platform Technologies: Due Date - Thursday, 30 November 5:00 pm Eastern, FBO Solicitation #: W15QKN-18-X-00NX, View RFI
RFI-18-07-PRISM-Medical Countermeasure Testing Platforms: Due Date - Thursday, 30 November 5:00 pm Eastern, FBO Solicitation #: W15QKN-18-X-00NY, View RFI
RFI-18-08-Improved Nerve Agent Treatment System (INATS)-MMB4: Due Date - Thursday, 30 November 5:00 pm Eastern, FBO Solicitation #: W15QKN-18-X-00NZ, View RFI
RFI-18-09-Improved Nerve Agent Treatment System (INATS)-Scopolamine: Due Date - Thursday, 30 November 5:00 pm Eastern, FBO Solicitation #: W15QKN-18-X-00O0, View RFI

November 15, 2017

RFI-18-05-Improved Nerve Agent Treatment System: Due Date - Friday, 1 December 5:00 Eastern, View RFI

October 27, 2017

RFI-18-04-Bacterial Biowarfare Agents: Due Date - Friday, 17 November 5:00 Eastern,View RFI (1) View RFI (2)

CLOSED SOLICITATIONS AND REQUESTS FOR INFORMATION

MCDC-RFI for JSTO/NCS (released September 13, 2017)
RFI-17-04: Burkholderia Species Immune Assays
RFI-17-05: Next Generation Devices for Delivery of Nucleic Acid Vaccines
RFI-17-06: Pharmaceutical-Based Agent Diagnostic Method, Assay or Platform
RFI-17-07: Smart Pills
RFI-17-08: Development of Novel, Quantitative, Ultra-sensitive Multiplex Molecular Diagnostics Platform for the Robust Multimodal Digital and/or Analog Detection of both Host-derived and Pathogen-derived Diagnostic Panels of Microbial Blood-Infection

MCDC-RPP-17-03 (released June 16, 2017)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required
PRE-17-06: (P) Execution of Phase 1 Clinical Study for Venezuelan Equine Encephalitis (VEE) Monovalent Virus Replicon Particle (VRP) vaccine
DET-17-07: (WP/P) Man-Portable Diagnostics System (MPDS) – Expanded Scope
DET-17-08: (WP/P) Chemical Exposure In Vitro Diagnostics (IVD) (ChemDx)

MCDC-RFI for MCM Platforms (released June 2, 2017)

RFI-17-03:  Sought information on the capabilities and willingness of private entities (non-profit and commercial) in platform technologies that can counter a variety of chemical and biological threat agents by standardizing product discovery, design, manufacturing, and/or testing to accelerate MCM delivery to the Warfighter.

MCDC-RPP-17-02 (released February 13, 2017)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required

17-03: Development of Marburgvirus (MARV) Vaccine Prototype against aerosolized MARV

17-04: Development of Multi-Target Single-Vector Vaccine Prototype against aerosolized Venezuelan Equine Encephalitis Virus (VEEV)

17-05: Man-Portable Diagnostics System (MPDS)

MCDC-RPP-17-01 (released January 17, 2017)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required

TRE-17-01: (P) Development of Monoclonal Antibody and Related Technologies as Medical Countermeasures against aerosolized Venezuelan Equine Encephalitis (VEE) Virus
TRE-17-02: (WP/P) Development of Efficacious Antiviral Countermeasures

MCDC-RFI for DBPAO (released January 17, 2017)
RFI-17-01: Sought information regarding qualifications on capability to produce, manufacture or provide inactive viral and bacterial antigens.
RFI-17-02: Sought information on third-party conformance testing.

MCDC-RPP-16-02 (released July 15, 2016)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required
TRE-16-03: (WP/P) Development of a Dual Drug Delivery Device (D4) Autoinjector
PRE-16-04: (WP/P) Lyophilized Formulation and Final Product Manufacturing Process for Western, Eastern, and Venezuelan equine encephalitis (WEVEE) Vaccine
PRE-16-05: (WP/P) Venezuelan equine encephalitis (VEE) Monovalent VLP Phase I Clinical Study
PRE-16-06: (WP/P) Eastern Equine Encephalitis Virus Advanced Technology Demonstration (EEEV ATD)


MCDC-RPP-16-01 (released June 22, 2016)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required

PRE-16-01: (P) Fill/Finish of Venezuelan Equine Encephalitis (VEE) virus like particle (VLP) Bulk Drug Product
PRE-16-02: (P) Development of Monoclonal Antibody Medical Countermeasures against Aerozolized Botulinum Toxin Serotypes A and B